Skip to main content

Table 4 Relation between combined densities of CD68 expression in both tumor nest and stroma and clinicopathologic characteristics

From: Pathologic assessment of tumor-associated macrophages and their histologic localization in invasive breast carcinoma

 

Total

CD68-positive TAMs

p

TNLow and TSLow

A

N = 17

N (%)

TNHigh and TSLow

B

N = 13

N (%)

TNHigh and TSHigh

C

N = 16

N (%)

TNLow and TSHigh

D

N = 14

N (%)

Age (years) mean ± SD

52.88 ± 13.71

51.23 ± 10.32

48.13 ± 12.25

51.22 ± 11.64

0.646

Size

 < 5 cm

39

13 (33.3)

12 (30.8)

4 (10.3)

10 (25.6)

0.001*

 ≥ 5 cm

21

4 (19)

1 (4.8)

12 (57.2)

4 (19)

Pairwise comparison: AB: 0.248, AC: 0.003*, AD:0.749, BC: < 0.001*, BD: 0.326, CD: 0.026*

 Grade

 GII

32

10 (31.3)

8 (25)

6 (18.7)

8 (25)

0.545

 GIII

28

7 (25)

5 (17.9)

10 (35.7)

6 (21.4)

Nodal metastasis

 Negative

26

12 (46.2)

5 (19.2)

4 (15.4)

5 (19.2)

0.053

 Positive

34

5 (14.7)

8 (23.5)

12 (35.3)

9 (26.5)

Stage

 I

3

2 (66.7)

1 (33.3)

0

0

0.119

 II

32

10 (31.3)

7 (21.9)

5 (15.5)

10 (31.3)

 III

25

5 (20)

5 (20)

11 (44)

14 (16)

Vascular invasion

 Negative

22

6 (27.3)

9 (40.9)

4 (18.2)

3 (13.6)

0.048*

 Positive

38

11 (28.9)

4 (10.5)

12 (31.7)

11 (28.9)

Pairwise comparison: AB: 0.139, AC: 0.707, AD: 0.456, BC: 0.027*, BD: 0.021*, CD:1

ER

 Negative

13

3 (23.1)

4 (30.7)

3 (23.1)

3 (23.1)

0.862

 Positive

47

14 (29.8)

9 (19.1)

13 (27.7)

11 (23.4)

PR

 Negative

26

7 (26.9)

7 (26.9)

5 (19.3)

7 (26.9)

0.628

 Positive

34

10 (29.4)

6 (17.6)

11 (32.4)

14 (20.6)

Her2

 Negative

45

12 (26.7)

11 (24.4)

12 (26.7)

10 (22.2)

0.845

 Positive

15

5 (33.3)

2 (13.3)

4 (26.7)

4 (26.7)

Ki-67

 ≤ 14%

29

8 (27.6)

7 (24.1)

6 (20.7)

8 (27.6)

0.745

 > 14%

31

9 (29)

6 (19.4)

10 (32.2)

6 (19.4)

Molecular subtypes

 Luminal A

27

7 (25.9)

7 (25.9)

5 (18.6)

8 (29.6)

0.284

 Luminal B

24

8 (33.3)

2 (8.4)

9 (37.5)

5 (20.8)

 Triple negative

9

2 (22.2)

4 (44.5)

2 (22.2)

1 (11.1)

  1. ER estrogen receptor, PR progesterone receptor, TAMs tumor-associated macrophage, TN tumor nest, TS tumor stroma
  2. *Statistically significant